RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug setrusumab during the class period from August 3, 2023, to December 26, 2025 [2][4][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][6]. - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed the risks associated with the Phase III Orbit study [4][6]. Group 2: Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a false impression of possessing reliable data on setrusumab while failing to disclose the risk of not achieving statistically significant results in the Phase III study [4]. - It is alleged that the company's optimism regarding the study's results was misplaced, as the Phase II results lacked a placebo control group, raising questions about the validity of the findings [4]. - Defendants' positive statements about the company's business and prospects were deemed materially misleading and lacking a reasonable basis [4]. Group 3: Investor Actions - Ultragenyx investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [6][8]. - Investors can choose to seek lead plaintiff status or remain absent class members [5][8]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [5][8].